🩸 Anticoagulant-Related Major Bleeding Reversal
This tool gives the specific reversal agent and general hemostatic support for anticoagulant-related major bleeding, by anticoagulant class.
Anticoagulant-Related Major Bleeding Reversal
Anticoagulant class
When to use
Use in major or life-threatening bleeding to pair the correct antidote with the drug class while applying general measures and planning restart.
How it works
VKA → vitamin K + 4F-PCC (or FFP). Dabigatran → idarucizumab (or PCC/dialysis). Xa inhibitor → andexanet alfa (or 4F-PCC). Heparin → protamine (1 mg per ~100 U).
Key points
- Specific antidotes are layered on top of universal first steps (stop the drug, mechanical hemostasis, transfusion support), not used in isolation. (original synthesis · not guideline verbatim)
- Dabigatran is dialyzable, offering an additional removal route unavailable for the Xa inhibitors.
- After bleeding control, restart timing weighs thrombotic risk (e.g. mechanical valve favors earlier restart).
References
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.